Arginine-directed glycation and decreased HDL plasma concentration and functionality

Nutrition and Diabetes

Volumn 4, Issue 9, 2014, Pages

  Godfrey, L ^a,c   Yamada Fowler, N ^a,d   Smith, J ^b   Thornalley, P J ^a   Rabbani, N ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Bruker Corporation   (United States)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN A1; ARGININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; METHYLGLYOXAL;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLYCATION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MALE; MEMBRANE FUSION; METABOLITE; MOLECULAR MODEL; NITRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PLASMA; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

EID: 84923279572     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.31     Document Type: Article

References (60)

1. Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065
3. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Populationbased resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet 2012; 8: e1003063
4. van der Steeg WA, Holme I, Boekholdt SM, Larsen M. L, Lindahl C, Stroes ESG et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: The IDEAL and EPIC-Norfolk Studies. J Am Coll Cardiol 2008; 51: 634-642
5. Rader DJ, Tall AR. The not-so-simple HDL story Is it time to revise the HDL cholesterol hypothesis? Nat Med 2012; 18: 1344-1346
6. Xue M, Rabbani N, Thornalley PJ. Glyoxalase in ageing. Semin Cell Dev Biol 2011; 22: 293-301
7. Beisswenger PJ, Wood ME, Howell SK, Touchette AD, O'Dell RM, Szwergold BS.-Oxoaldehydes increase in the postprandial period and reflect the degree of hyperglycaemia. Diabetes Care 2001; 24: 726-732
8. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 1994; 87: 21-29
9. Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011; 22: 309-317
10. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF et al. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis 2009; 205: 590-594
11. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005; 48: 1590-1603
12. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16: 1471-1485
13. Rabbani N, Thornalley PJ. Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids 2012; 42: 1133-1142
14. McPherson PAC, Young IS, McKibben B, McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J Lipid Res 2007; 48: 86-95
15. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353
16. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665: 408-419
17. Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW, Oda MN. The Interplay between Size, morphology, stability, and functionality of high-density lipoprotein subclasses. Biochemistry 2008; 47: 4770-4779
18. Rabbani N, Varma Chittari M, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL in patients with type 2 diabetes and effect of metformin. Diabetes 2010; 59: 1038-1045
19. Tall A, Granot E, Brocia R, Tabas I, Hesler C, Williams K et al. Accelerated transfer of cholesteryl esters in dyslipidemic plasma-role of cholesteryl ester transfer protein. J Clin Invest 1987; 79: 1217-1225
20. Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res 1992; 33: 1807-1816
21. Connolly DT, Heuvelman D, Glenn K. Inactivation of cholesteryl ester transfer protein by cysteine modification. Biochem Biophys Res Commun 1996; 223: 42-47
22. Hope HR, Heuvelman D, Duffin K, Smith C, Zablocki J, Schilling R et al. Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: involvement of a critical cysteine. J Lipid Res 2000; 41: 1604-1614
23. Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R et al. Conversion of low density lipoprotein to the pro-atherogenic form by methylglyoxal with increased arterial proteoglycan binding and aortal retention. Diabetes 2011; 60: 1973-1980
24. Ahmed N, Dobler D, Dean M, Thornalley PJ. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 2005; 280: 5724-5732
25. Silva RA, Huang R, Morris J, Fang J, Gracheva EO, Ren G et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci USA 2008; 105: 12176-12181
26. Segrest JP, Jones MK, Klon AE, Sheldahl CJ, Hellinger M, De Loof H et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J Biol Chem 1999; 274: 31755-31758
27. Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N et al. COPASI-COmplex PAthway SImulator. Bioinformatics 2006; 22: 3067-3074
28. Frenais R, Ouguerram K, Maugeais C, Mahot P, Maugere P, Krempf M et al. High density lipoprotein apolipoprotein Al kinetics in NIDDM: A stable isotope study. Diabetologia 1997; 40: 578-583
29. Anderson DW, Nichols AV, Forte TM, Lindgren FT. Particle distribution of human serum high density lipoproteins. Biochim Biophys Acta 1977; 493: 55-68
30. Arsenault BJ, Lemieux I, Despres JP, Gagnon P, Wareham NJ, Stroes ESG et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Atherosclerosis 2009; 206: 276-281
31. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circulation Research 2005; 96: 1221-1232
32. Webb NR, Connell PM, Graf GA, Smart EJ, de Villiers WJS, de Beer FC et al. SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J Biol Chem 1998; 273: 15241-15248
33. Guendouzi K, Collet X, Perret B, Chap H, Barbaras R. Remnant high density lipoprotein2 particles produced by hepatic lipase display high-affinity binding and increased endocytosis into a human hepatoma cell line (HEPG2). Biochemistry 1998; 37: 14974-14980
34. Lewis GF, Lamarche B, Uffelman KD, Heatherington AC, Honig MA, Szeto LW et al. Clearance of postprandial and lipolytically modified human HDL in rabbits and rats. J Lipid Res 1997; 38: 1771-1778
35. Eisenberg S, Windmueller HG, Levy RI. Metabolic fate of rat and human lipoprotein apoproteins in the rat. J Lipid Res 1973; 14: 446-458
36. Huang R, Silva RAG, Jerome WG, Kontush A, Chapman MJ, Curtiss LK et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011; 18: 416-422
37. Mei X, Atkinson D. Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization. J Biol Chem 2011; 286: 38570-38582
38. Thompson PD, Cullinane EM, Sady SP, Flynn MM, Bernier DN, Kantor MA et al. Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training. Circulation 1988; 78: 25-34
39. Rabbani N, Thornalley PJ. Dicarbonyls (glyoxal, methylglyoxal, and 3-deoxyglucosone). In: Niwa T (ed.), Uremic Toxins. John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2012. pp 177-192
40. Annema W, von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432-2448
41. Kurosaki Y, Tsukushi T, Munekata S, Akahoshi T, Moriya T, Ogawa Z. Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J Clin Lab Analysis 2013; 27: 231-236
42. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by ApoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle-size. Arterioscler Thromb 1994; 14: 707-720
43. Krikken JA, Gansevoort RT, Dullaart RPFon behalf of the PSG. Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease. J Lipid Res 2010; 51: 1982-1990
44. Dhar A, Dhar I, Jiang B, Desai KM, Wu L. Chronic methylglyoxal infusion by minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 2011; 60: 899-908
45. Bashtovyy D, Jones MK, Anantharamaiah GM, Segrest JP. Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J Lipid Res 2011; 52: 435-450
46. de Beer MC, Durbin DM, Cai L, Jonas A, de Beer FC, van der Westhuyzen DR. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. J Lipid Res 2001; 42: 309-313
47. Roosbeek S, Vanloo B, Duverger N, Caster H, Breyne J, De Beun I et al. Three arginine residues in apolipoprotein A-I are critical for activation of lecithin: cholesterol acyltransferase. J Lipid Res 2001; 42: 31-40
48. Shao BH, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-1. Proc Natl Acad Sci USA 2008; 105: 12224-12229
49. Shao BH, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 2012; 287: 6375-6386
50. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-320
51. Calvo C, Ulloa N, Campos M, Verdugo C, Ayrault-Jarrier M. The preferential site of non-enzymatic glycation of human apolipoprotein A-I in vivo. Clin Chim Acta 1993; 217: 193-198
52. Calvo C, Talussot C, Ponsin G, Berthezene F. Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem Biophys Res Commun 1988; 153: 1060-1067
53. Jones MK, Gu F, Catte A, Li L, Segrest JP. "Sticky" and "promiscuous", the yin and yang of apolipoprotein A-I termini in discoidal high-density lipoproteins: A combined computational-experimental approach. Biochemistry 2011; 50: 2249-2263
54. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 2007; 50: 643-653
55. Zhang L, Yan F, Zhang S, Lei D, Charles M. A, Cavigiolio G et al. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol 2012; 8: 342-349
56. Ranalletta M, Bierilo KK, Chen Y, Milot D, Chen Q, Tung E et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010; 51: 2739-2752
57. Rizzo M, Otvos JD, Nikolic D, Montalto G, Toth PP, Banach M. Subfractions and subpopulations of HDL: an update. Curr Med Chem 2014; 21: 2881-2891
58. Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: A stable isotope study. J Am Soc Nephrol 2004; 15: 1008-1015
59. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15
60. Berthold HK, Rizzo M, Spenrath N, Montalto G, Krone W, Gouni-Berthold I. Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial. PLoS One 2014; 9: e91565.